Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term coramitug extension study in transthyretin amyloid cardiomyopathy
NL-OMON60631Phase 2Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of coramitug in amyloidotic transthyretin cardiomyopathy (ATTR-CM), sponsored by Novo Nordisk. Primary endpoint: Treatment-emergent adverse events. Started Jan 2025; status: active, not recruiting.
02
Drugs
coramitug
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NL-OMON60631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60631.